Elliott Jeffrey Thomas 的 Form 4/A 修正申報
修正Exact Sciences Corp（EXAS），2021/8/3 申報
- 申報編號
- 0001209191-21-049201
- 申報時間
- 2021/8/3
- 交易日
- 2021/4/30-7/29
- 申報延遲
- 95 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/8/2
這份申報列了 9 筆非衍生性交易。公開市場賣出合計 $427.4 萬。交易後 95 天申報。
這份修正申報取代了 0001209191-21-049081（2021/8/2 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Elliott Jeffrey ThomasCIK 0001689757 | 高階主管（財務長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/4/30 | Common Stock | A公司授予取得 | +206 | $103.22 | +$21,263.32 | 38,567 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −1,200 | $107.54F2 | −$129,048 | 37,367 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −1,066 | $108.54F3 | −$115,703.64 | 36,301 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −2,602 | $109.58F4 | −$285,127.16 | 33,699 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −7,818 | $110.64F5 | −$864,983.52 | 25,881 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −13,853 | $111.58F6 | −$1,545,717.74 | 12,028 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −8,675 | $112.39F7 | −$974,983.25 | 3,353 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −1,899 | $113.35F8 | −$215,251.65 | 1,454 | 直接 | |
| 2021/7/29 | Common Stock | S賣出處分 | −1,248 | $114.41F9 | −$142,783.68 | 206 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.16 to $107.92, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.23 to $108.73, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $110.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.998, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.02 to $113.895, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.165 to $114.63, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F10
In addition to the shares of Common Stock reported on this Form 4, which total 1,396 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
備註
On August 2, 2021 the reporting person filed a Form 4 to report certain sales made pursuant to a Rule 10bb5-1 trading plan entered into in November 2020 (the "Trading Plan"). This Form 4/A is being filed solely to denote that the reported sales were made pursuant to the Trading Plan.